-- Robert Preidt
TUESDAY, Oct. 23 (HealthDay News) -- Using antiviral drugs to
treat patients with chronic hepatitis C infection may greatly
reduce their risk of liver cancer, according to a new study.
Hepatitis C is a leading cause of liver cancer and other liver
diseases and is the leading cause of liver transplants. According
to the U.S. Centers for Disease Control and Prevention, each year
more than 15,000 Americans die from hepatitis C-related illness,
such as cirrhosis and liver cancer. Deaths from the virus have been
increasing for over a decade and are expected to increase in the
In the new study, Nina Kimer and colleagues at Copenhagen
University in Denmark reviewed eight published clinical trials on
the use of antiviral therapy -- interferon or pegylated interferon,
or ribavirin, or a combination -- in patients with chronic
hepatitis C infection.
Almost 1,200 patients in the studies received antiviral therapy.
Most of them received interferon. The patients' antiviral treatment
lasted between six months and a year and they were monitored for
between five and eight years after treatment, along with another
nearly 1,200 patients who did not receive antiviral treatment.
During follow-up, liver cancer was diagnosed in 81 patients who
received antiviral treatment and in 129 patients who did not
receive antiviral treatment. The Danish researchers concluded that
antiviral therapy reduced the risk of liver cancer by 47
One expert not connected to the study said the results were
"This study confirms something that most of us who treat hepatitis C knew on a gut level but had never seen demonstrated so effectively," said Dr. Douglas Dieterich, professor of liver diseases at Mount Sinai School of Medicine in New York City. Liver cancer "is the fastest growing cancer in the U.S., so this gives us great hope that by treating hepatitis C, we can now not only cure the virus but prevent [liver cancer] in the future," he said.
The findings are published Oct. 23 in the journal
The researchers also reviewed five other studies of patients
with chronic hepatitis C infection and said those findings showed
that antiviral treatment reduced the risk of liver cancer by 70
The authors noted in a journal news release that standard
treatment now consists of interferon plus ribavirin, which is
considered more effective than either alone, and that the infection
is usually identified earlier now than it used to be, before it
causes extensive damage.
Another expert said that other treatment approaches might even
exceed the results noted in this study.
"If we are able to extrapolate this data to the newer approved standard-of-care therapies, which have sustained viral response rates of greater than 70 percent, one would expect that these results would be even better in preventing the development of primary liver cancer," said Dr. David Bernstein, chief of the division of hepatology at North Shore University Hospital in Manhasset, N.Y. These improved outcomes "should encourage physicians to treat patient with advanced fibrosis and cirrhosis, and encourage those patients to seek out therapy," he added.
The U.S. National Institute of Allergy and Infectious Diseases
has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.